Clinical trials: Malignant Tumor With Metastasis
Metastatic Pancreatic Ductal Adenocarcinoma
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
The PANOVA-4 study is designed to evaluate the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with atezolizumab, gemcitabine and nab-paclitaxel, for the treatment of metastatic pancreatic cancer.
- Trial name
- NCT06390059
- Testing
- Tumor Treating Fields, Atezolizumab, Gemcitabine
- Where
- 15 sites in Czechia, Germany and 2 more
- Volunteers
- 84 people
- Sponsor
- NovoCure Ltd.
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors.
- Trial name
- FLAGSHP-1 (NCT04670679)
- Testing
- ERAS-601, Cetuximab, Pembrolizumab
- Where
- 14 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Erasca, Inc.
Prostate Cancer
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
The main objective of this study is to evaluate the effects of PLX3397 on male subjects with CRPC. Secondary objectives include evaluating the safety and tolerability of PLX3397 and the anti-tumor effects that PLX3397 has on the…
- Trial name
- NCT01499043
- Testing
- PLX3397
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Daiichi Sankyo
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc)
Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT
The purpose of this multicenter pragmatic randomized controlled trial is to determine whether AI-assisted interpretation of multiphasic liver contrast-enhanced computed tomography (CE-CT) is non-inferior to standard radiology…
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Hepatic Metastasis, Hepatic Hemangioma
- Trial name
- NCT07768085
- Testing
- AI-assisted abdominal CE-CT reporting, Standard abdominal CE-CT reporting without AI assistance
- Where
- China
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Thyroid Cancer
Tumor Microenvironmental Collagen Signature to Predict Thyroid Cancer Superior Mediastinal Lymph Node Metastasis
About 7-13% thyroid cancer patients have superior mediastinal lymph node metastasis, but its clinical identification is insufficient. Effective and individualized identification strategy need to be studied.
- Trial name
- TC-CS-SMLNM (NCT06791174)
- Where
- China
- Volunteers
- 181 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Unspecified Adult Solid Tumor, Protocol Specific
Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004090
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Sponsor
- Northwestern University
Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone.
- Conditions
- Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma
- Trial name
- NCT04071223
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 47 sites in United States
- Volunteers
- 98 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
- Conditions
- Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive
- Trial name
- NCT06714617
- Testing
- BL-M17D1
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- SystImmune Inc.
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Melphalan in Patients With Neoplastic Meningitis
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of melphalan in patients with persistent or recurrent…
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Leukemia, Lymphoma
- Trial name
- NCT00002750
- Testing
- melphalan
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Solid Tumor
Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors
To evaluate CAN1012 when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.
- Trial name
- NCT05580991
- Testing
- CAN1012
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Canwell Biotech Limited
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
Gastrointestinal Tumors
Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)
This is an open, multi-cohort, multi-center, exploratory and phase II clinical trial. To evaluate the efficacy and safety Anlotinib combined with chemotherapy as first-line and maintenance therapy for Gastrointestinal Tumors with…
- Trial name
- ALTER-G-001 (NCT05262335)
- Testing
- Anlotinib + Oxaliplatin + Capecitabine, Anlotinib + Cisplatin + Paclitaxel/ Docetaxel, Anlotinib + Standard first-line chemotherapy
- Where
- 7 sites in China
- Volunteers
- 116 people
- Sponsor
- Ruijin Hospital
Breast Carcinoma, Digestive System Neoplasm
Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
This phase I trial collects blood samples to investigate the prevalence of changes in genes (genetic mutations) in solid tumor patient populations seeking care at Mayo Clinic Embedded Cancer Center at St. Vincent's Riverside.
- Conditions
- Breast Carcinoma, Digestive System Neoplasm, Malignant Brain Neoplasm, Malignant Central Nervous System Neoplasm
- Trial name
- NCT04456140
- Testing
- Biospecimen Collection, Genetic Counseling, Genetic Testing
- Where
- 2 sites in United States
- Volunteers
- 230 people
- Sponsor
- Mayo Clinic
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma
- Trial name
- NCT03878524
- Testing
- Abemaciclib, Abiraterone, Afatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
HER-2 Protein Overexpression, HER-2 Gene Amplification
Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor
HER2 signaling pathway abnormalities or HER2 overexpression can be seen in various types of solid tumors apart from breast cancer or hepatic cancer.
- Trial name
- BIOs-Her (NCT04215159)
- Testing
- Trastuzumab biosimilar, Gemcitabine Hydrochloride, Irinotecan Hydrochloride
- Volunteers
- 42 people
- Sponsor
- Jin-Hee Ahn
Chronic Myeloproliferative Disorders, Leukemia
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of decitabine in treating patients with stage III or stage…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002980
- Testing
- decitabine
- Where
- 4 sites in United States
- Sponsor
- California Cancer Consortium
Muscle-Invasive Bladder Carcinoma
Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer
In this phase II study, eligible patients will be treated with maximal tumor resection and then started treatment within 8 weeks. Chemotherapy, Nivolumab and radiotherapy (RT) will be started on day one.
- Trial name
- CNN-BC (NCT05203913)
- Testing
- Nivolumab, Nab paclitaxel, Cisplatin
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Liver Metastasis
Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid Tumor
The purpose of this study is to see if treatment with intrahepatic chemotherapy is a good options in patients with liver metastases.
- Trial name
- NCT01511146
- Testing
- Oxaliplatin, Mitomycin + Gemcitabine
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Copenhagen University Hospital at Herlev
Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor
Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases
The purpose of this neoadjuvant trial is to evaluate efficacy and toxicity of chemotherapy using weekly paclitaxel (arm A) versus the combination of the cdk 4/6 inhibitor palbociclib and standard endocrine treatment (arm B).
- Trial name
- PREDIX LumB (NCT02603679)
- Testing
- Paclitaxel, Tamoxifen + Palbociclib, Aromatase Inhibitor + Palbociclib
- Where
- 3 sites in Sweden
- Volunteers
- 181 people
- Sponsor
- Thomas Hatschek
Metastatic Brain Tumor
Markers of Prognosis and Response to Therapy in Patients With Metastatic Brain Tumors Undergoing Stereotactic Radiosurgery (SRS)
This registry study will evaluate patients with metastatic brain tumors undergoing, or having undergone, stereotactic radiosurgery (SRS) at Swedish Medical Center.
- Trial name
- NCT01908179
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Swedish Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.